Open Payments

GEISINGER MEDICAL CENTER

Type
Teaching hospital
Where
POTTSVILLE, PA
Medicare CCN
390006
Received
$1,179,005 in 238 records, 2019 ($738,887 general, $440,118 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2019General payment76$738,887
2019Research payment162$440,118

By company

CompanyRecordsAmountYears
Merck Sharp & Dohme LLC61$561,0492019
Novo Nordisk Inc2$115,0002019
Novo Nordisk AS60$99,0252019
CSL Behring26$83,1172019
Medtronic MiniMed, Inc.4$54,1192019
OpGen, Inc.2$52,3752019
BioFire Diagnostics, LLC14$44,3402019
Roche Diagnostics Corporation6$34,2002019
B. Braun Medical Inc.1$30,0002019
Covidien LP2$30,0002019
Endologix LLC1$20,8752019
Siemens Medical Solutions USA, Inc.3$13,9832019
DiaSorin Molecular LLC1$8,3952019
Medtronic USA, Inc.2$6,0502019
Insulet Corporation10$5,6322019
Medline Industries LP1$4,4002019
Zimmer Biomet Holdings, Inc.2$3,0882019
Medical Device Business Services, Inc.1$2,9762019
KARL STORZ Endoscopy-America7$2,6402019
Stryker Corporation17$1,7302019
Linvatec Corporation1$1,3742019
Olympus America Inc.2$1,3192019
Janssen Pharmaceuticals, Inc2$1,2502019
Advanced Respiratory, Inc1$5002019
Masimo Corporation1$5002019
Ethicon US, LLC1$3502019
Oticon Medical, LLC1$3282019
E.R. Squibb & Sons, L.L.C.1$1512019
EMD Millipore Corporation3$892019
Medtronic Vascular, Inc.1$862019
Luminex Molecular Diagnostics1$582019

By nature of payment

NatureRecordsAmount
Consulting Fee9$587,933
Research payment162$440,118
Compensation for services other than consulting, including serving as faculty or as a speaker at a v31$62,781
Grant5$37,350
Charitable Contribution3$35,422
Space rental or facility fees (teaching hospital only)12$11,900
Gift10$2,748
Education1$328
Food and Beverage1$275
Royalty or License3$89
Honoraria1$58

Records

DateCompanyAmountNatureFormProductStudyYear
2019-12-31Siemens Medical Solutions USA, Inc.$12,375Research paymentCash or cash equivalentGEISINGER2018MRIPR887923926Fielden2019
2019-12-31Linvatec Corporation$1,374GrantIn-kind items and servicesHALL POWER Device, ORTHOPEDIC SURGERY2019
2019-12-31Siemens Medical Solutions USA, Inc.$1,022Charitable ContributionIn-kind items and services2019
2019-12-31Siemens Medical Solutions USA, Inc.$586Research paymentCash or cash equivalentGeisinger2019MRIPR724Haggerty2019
2019-12-31Zimmer Biomet Holdings, Inc.$88GiftIn-kind items and servicesZimmer Biomet Instruments and Implants Device, General2019
2019-12-31Novo Nordisk AS$72Research paymentIn-kind items and servicesNN9931-42962019
2019-12-31Stryker Corporation$0GiftCash or cash equivalentNONE Device, NONE2019
2019-12-23Novo Nordisk AS$737Research paymentCash or cash equivalentEX9536-43882019
2019-12-19Novo Nordisk AS$3,247Research paymentCash or cash equivalentNN9931-42962019
2019-12-19Novo Nordisk AS$671Research paymentCash or cash equivalentNN9931-42962019
2019-12-19Novo Nordisk AS$380Research paymentCash or cash equivalentNN9931-42962019
2019-12-19Novo Nordisk AS$192Research paymentCash or cash equivalentEX9536-43882019
2019-12-19BioFire Diagnostics, LLC$13Research paymentIn-kind items and servicesFilmArray System Device, Clinical DiagnosticsFilmArray BJI Pivotal Study2019
2019-12-18Luminex Molecular Diagnostics$58HonorariaIn-kind items and services Medical Supply, Product2019
2019-12-17Medtronic MiniMed, Inc.$11,976Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentMinimed 670G System Device, Durable Pump2019
2019-12-17BioFire Diagnostics, LLC$3,727Research paymentCash or cash equivalentFilmArray System Device, Clinical DiagnosticsFilmArray BJI Pivotal Study2019
2019-12-17Medical Device Business Services, Inc.$2,976GrantCash or cash equivalent2019
2019-12-17Insulet Corporation$704Compensation for services other than consulting, including serving as faculty or as a speaker at a v (10 payments)Cash or cash equivalentOmnipod Device, Insulin Pump2019
2019-12-16Novo Nordisk AS$24Research paymentIn-kind items and servicesEX9536-43882019
2019-12-10CSL Behring$1,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2019
2019-12-09Merck Sharp & Dohme LLC$6Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR2019
2019-12-05CSL Behring$285Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-12-03Novo Nordisk AS$2,250Research paymentCash or cash equivalentEX9536-43882019
2019-11-30Novo Nordisk AS$72Research paymentIn-kind items and servicesNN9931-42962019
2019-11-29Novo Nordisk Inc$50,000Research paymentCash or cash equivalentDecade plus,What relationship b/n longterm weight maint, clinical relevance&healthcare utilization?2019
2019-11-26Oticon Medical, LLC$328Education (14 payments)Cash or cash equivalentPONTO BONE ANCHORED HEARING SYSTEM Device, Medical Device2019
2019-11-22Merck Sharp & Dohme LLC$5,000Research paymentCash or cash equivalentKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy2019
2019-11-21Insulet Corporation$352Compensation for services other than consulting, including serving as faculty or as a speaker at a v (10 payments)Cash or cash equivalentOmnipod Device, Insulin Pump2019
2019-11-19Roche Diagnostics Corporation$600Consulting FeeCash or cash equivalentCD cobas Automation Device, Centralized Diagnostics2019
2019-11-15Covidien LP$20,000GrantCash or cash equivalent2019
2019-11-14Janssen Pharmaceuticals, Inc$750Space rental or facility fees (teaching hospital only)Cash or cash equivalentINVOKANA Drug, Cardiovascular & Metabolism2019
2019-11-11BioFire Diagnostics, LLC$9,000Research paymentIn-kind items and servicesFilmArray System Device, Clinical DiagnosticsFilmArray BJI Pivotal Study2019
2019-11-11BioFire Diagnostics, LLC$3,869Research paymentCash or cash equivalentFilmArray System Device, Clinical DiagnosticsFilmArray BJI Pivotal Study2019
2019-11-07CSL Behring$2,366Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-11-07CSL Behring$1,403Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-11-07CSL Behring$150Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-11-07CSL Behring$50Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-11-06KARL STORZ Endoscopy-America$690GiftIn-kind items and servicesTELESCOPE,HOPKINS II,AUTOCLAV, Device, UROLOGY2019
2019-11-06Insulet Corporation$352Compensation for services other than consulting, including serving as faculty or as a speaker at a v (10 payments)Cash or cash equivalentOmnipod Device, Insulin Pump2019
2019-11-06KARL STORZ Endoscopy-America$30GiftIn-kind items and servicesTELESCOPE, HOPKINS II, 0', 4MM DIAMETER Device, ENT2019
2019-11-06KARL STORZ Endoscopy-America$30GiftIn-kind items and servicesTELESCOPE,HOPKINS II FWD OBLG Device, GYNECOLOGY2019
2019-11-01Merck Sharp & Dohme LLC$178,765Consulting FeeCash or cash equivalent2019
2019-10-31Novo Nordisk AS$72Research paymentIn-kind items and servicesNN9931-42962019
2019-10-29OpGen, Inc.$15,000Research paymentCash or cash equivalentAcuitas AMR Gene Panel Urine Clinical Performance Evaluation2019
2019-10-29Novo Nordisk AS$3,081Research paymentCash or cash equivalentEX9536-43882019
2019-10-29Novo Nordisk AS$1,540Research paymentCash or cash equivalentNN9931-42962019
2019-10-24BioFire Diagnostics, LLC$2,242Research paymentCash or cash equivalentFilmArray System Device, Clinical DiagnosticsFilmArray BJI Pivotal Study2019
2019-10-24CSL Behring$400Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-10-24Insulet Corporation$352Compensation for services other than consulting, including serving as faculty or as a speaker at a v (10 payments)Cash or cash equivalentOmnipod Device, Insulin Pump2019
2019-10-22BioFire Diagnostics, LLC$9,036Research paymentIn-kind items and servicesFilmArray System Device, Clinical DiagnosticsFilmArray BJI Pivotal Study2019
2019-10-10CSL Behring$8,842Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-10-10CSL Behring$1,123Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-10-10CSL Behring$50Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-10-09Stryker Corporation$429Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREPROCESSED DEVICE Device, HYGIA HEALTH SERVICES2019
2019-10-09Stryker Corporation$175Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREPROCESSED DEVICE Device, HYGIA HEALTH SERVICES2019
2019-10-09Stryker Corporation$42Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREPROCESSED DEVICE Device, HYGIA HEALTH SERVICES2019
2019-10-09Stryker Corporation$17Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREPROCESSED DEVICE Device, HYGIA HEALTH SERVICES2019
2019-10-03Endologix LLC$20,875Research paymentCash or cash equivalentAFX Device, Cardiology/Vascular DiseasesLEOPARD2019
2019-10-03Novo Nordisk AS$3,247Research paymentCash or cash equivalentNN9931-42962019
2019-10-03Novo Nordisk AS$380Research paymentCash or cash equivalentNN9931-42962019
2019-10-01BioFire Diagnostics, LLC$4,500Research paymentIn-kind items and servicesFilmArray System Device, Clinical DiagnosticsFilmArray BJI Pivotal Study2019
2019-10-01BioFire Diagnostics, LLC$4,500Research paymentIn-kind items and servicesFilmArray System Device, Clinical DiagnosticsFilmArray BJI Pivotal Study2019
2019-10-01Insulet Corporation$352Compensation for services other than consulting, including serving as faculty or as a speaker at a v (10 payments)Cash or cash equivalentOmnipod Device, Insulin Pump2019
2019-10-01Novo Nordisk AS$75Research paymentIn-kind items and servicesEX9536-43882019
2019-09-30Medtronic Vascular, Inc.$86Research paymentIn-kind items and servicesECG Belt2019
2019-09-30Novo Nordisk AS$72Research paymentIn-kind items and servicesNN9931-42962019
2019-09-26Novo Nordisk AS$2,233Research paymentCash or cash equivalentNN9931-42962019
2019-09-26Novo Nordisk AS$737Research paymentCash or cash equivalentEX9536-43882019
2019-09-25Medtronic MiniMed, Inc.$17,415Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentMinimed 670G System Device, Durable Pump2019
2019-09-18Masimo Corporation$500Space rental or facility fees (teaching hospital only)Cash or cash equivalentSET and rainbow SET Device, Devices2019
2019-09-17CSL Behring$5,585Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-09-17CSL Behring$50Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-09-10E.R. Squibb & Sons, L.L.C.$151Research paymentCash or cash equivalentELIQUIS Drug, CardiovascularPhase III VTE Prev in Children w ALL2019
2019-09-06Novo Nordisk AS$24Research paymentIn-kind items and servicesEX9536-43882019
2019-08-31Novo Nordisk AS$72Research paymentIn-kind items and servicesNN9931-42962019
2019-08-30Novo Nordisk AS$2,425Research paymentCash or cash equivalentNN9931-42962019
2019-08-30Novo Nordisk AS$691Research paymentCash or cash equivalentEX9536-43882019
2019-08-30Novo Nordisk AS$380Research paymentCash or cash equivalentNN9931-42962019
2019-08-27Roche Diagnostics Corporation$7,900Consulting FeeCash or cash equivalentCD cobas Automation Device, Centralized Diagnostics2019
2019-08-22CSL Behring$500Space rental or facility fees (teaching hospital only)Cash or cash equivalent2019
2019-08-22Ethicon US, LLC$350Space rental or facility fees (teaching hospital only)Cash or cash equivalentDERMABOND Portfolio Device, Wound Closure2019
2019-08-13CSL Behring$18,605Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-08-13Novo Nordisk AS$3,247Research paymentCash or cash equivalentNN9931-42962019
2019-08-13CSL Behring$550Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-08-13Novo Nordisk AS$380Research paymentCash or cash equivalentNN9931-42962019
2019-08-08Merck Sharp & Dohme LLC$38Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR2019
2019-08-08Merck Sharp & Dohme LLC$35Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR2019
2019-08-08Merck Sharp & Dohme LLC$20Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy2019
2019-08-08Merck Sharp & Dohme LLC$3Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR2019
2019-08-08Merck Sharp & Dohme LLC$2Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR2019
2019-08-08Merck Sharp & Dohme LLC$2Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR2019
2019-08-08Merck Sharp & Dohme LLC$2Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR2019
2019-08-08Merck Sharp & Dohme LLC$1Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR2019
2019-08-08Merck Sharp & Dohme LLC$0Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR2019
2019-08-08Merck Sharp & Dohme LLC$0Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR2019
2019-08-01Merck Sharp & Dohme LLC$142,863Consulting FeeCash or cash equivalent2019
2019-07-31Novo Nordisk AS$72Research paymentIn-kind items and servicesNN9931-42962019
2019-07-30Novo Nordisk AS$2,389Research paymentCash or cash equivalentEX9536-43882019
2019-07-30Novo Nordisk AS$1,985Research paymentCash or cash equivalentNN9931-42962019
2019-07-30Insulet Corporation$704Compensation for services other than consulting, including serving as faculty or as a speaker at a v (10 payments)Cash or cash equivalentOmnipod Device, Insulin Pump2019
2019-07-30Novo Nordisk AS$634Research paymentCash or cash equivalentNN9931-42962019
2019-07-29EMD Millipore Corporation$31Royalty or LicenseCash or cash equivalent Device, DIAGNOSTIC TESTING2019
2019-07-29EMD Millipore Corporation$28Royalty or LicenseCash or cash equivalent Device, DIAGNOSTIC TESTING2019
2019-07-17B. Braun Medical Inc.$30,000Charitable ContributionCash or cash equivalent2019
2019-07-16Novo Nordisk AS$3,247Research paymentCash or cash equivalentNN9931-42962019
2019-07-16Zimmer Biomet Holdings, Inc.$3,000GrantCash or cash equivalentCMF Non Device, CMF & Thoracic2019
2019-07-16Stryker Corporation$191Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREPROCESSED DEVICE Device, HYGIA HEALTH SERVICES2019
2019-07-16Stryker Corporation$59Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREPROCESSED DEVICE Device, HYGIA HEALTH SERVICES2019
2019-07-16Stryker Corporation$36Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREPROCESSED DEVICE Device, HYGIA HEALTH SERVICES2019
2019-07-16Stryker Corporation$19Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREPROCESSED DEVICE Device, HYGIA HEALTH SERVICES2019
2019-07-11OpGen, Inc.$37,375Research paymentCash or cash equivalentAcutias AMR Gene Panel Urine Clinical Performance Evaluation2019
2019-07-11CSL Behring$2,849Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-07-10Insulet Corporation$352Compensation for services other than consulting, including serving as faculty or as a speaker at a v (10 payments)Cash or cash equivalentOmnipod Device, Insulin Pump2019
2019-07-09Medline Industries LP$4,400Charitable ContributionCash or cash equivalent2019
2019-07-09KARL STORZ Endoscopy-America$270GiftIn-kind items and servicesLIGHT CABLE, 3.5MM X 300CM. LGTH 9.8 FT Device, VIDEOIMAGING2019
2019-07-02Novo Nordisk AS$3,247Research paymentCash or cash equivalentNN9931-42962019
2019-07-02Novo Nordisk AS$1,140Research paymentCash or cash equivalentNN9931-42962019
2019-07-02Novo Nordisk AS$1,000Research paymentCash or cash equivalentNN9931-42962019
2019-06-30Novo Nordisk AS$72Research paymentIn-kind items and servicesNN9931-42962019
2019-06-28Advanced Respiratory, Inc$500Space rental or facility fees (teaching hospital only)Cash or cash equivalentThe MetaNeb System Device, Airway Clearance Device2019
2019-06-28KARL STORZ Endoscopy-America$450GiftIn-kind items and servicesTELESCOPE,HOPKINS II,AUTOCLAV, Device, UROLOGY2019
2019-06-28KARL STORZ Endoscopy-America$420GiftIn-kind items and servicesLIGHT CABLE, 3.5MM X 300CM. LGTH 9.8 FT Device, VIDEOIMAGING2019
2019-06-26Medtronic MiniMed, Inc.$18,036Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentMinimed 670G System Device, Durable Pump2019
2019-06-25Novo Nordisk AS$1,754Research paymentCash or cash equivalentNN9931-42962019
2019-06-25BioFire Diagnostics, LLC$1,500Research paymentIn-kind items and servicesFilmArray System Device, Clinical DiagnosticsFilmArray BJI Pivotal Study2019
2019-06-25BioFire Diagnostics, LLC$1,500Research paymentIn-kind items and servicesFilmArray System Device, Clinical DiagnosticsFilmArray BJI Pivotal Study2019
2019-06-11CSL Behring$13,367Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-06-11CSL Behring$600Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-06-10CSL Behring$750Space rental or facility fees (teaching hospital only)Cash or cash equivalent2019
2019-06-06BioFire Diagnostics, LLC$275Food and Beverage (10 payments)In-kind items and services Device, Clinical Diagnostics2019
2019-06-05Novo Nordisk AS$24Research paymentIn-kind items and servicesEX9536-43882019
2019-06-05Novo Nordisk AS$6Research paymentIn-kind items and servicesNN9931-42962019
2019-06-03Novo Nordisk AS$174Research paymentIn-kind items and servicesNN9931-42962019
2019-05-31Novo Nordisk AS$72Research paymentIn-kind items and servicesNN9931-42962019
2019-05-30Novo Nordisk Inc$65,000Research paymentCash or cash equivalentDecade plus,What relationship b/n longterm weight maint, clinical relevance&healthcare utilization?2019
2019-05-28Novo Nordisk AS$14,365Research paymentCash or cash equivalentNN9931-42962019
2019-05-28Novo Nordisk AS$5,120Research paymentCash or cash equivalentEX9536-43882019
2019-05-21Roche Diagnostics Corporation$5,800Consulting FeeCash or cash equivalentCD cobas Analyzer Series Device, Centralized Diagnostics2019
2019-05-15Covidien LP$10,000GrantCash or cash equivalent2019
2019-05-10Medtronic USA, Inc.$2,050Space rental or facility fees (teaching hospital only)Cash or cash equivalentMazorX - Renaissance Device, Enabling2019
2019-05-09CSL Behring$3,368Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-05-09Insulet Corporation$352Compensation for services other than consulting, including serving as faculty or as a speaker at a v (10 payments)Cash or cash equivalentOmnipod Device, Insulin Pump2019
2019-05-09CSL Behring$300Research paymentCash or cash equivalentStudy to Investigate CSL112 in Subjects With Acute Coronary Syndrome AEGIS-II2019
2019-05-08Merck Sharp & Dohme LLC$72Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy2019
2019-05-08Merck Sharp & Dohme LLC$72Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy2019
2019-05-08Merck Sharp & Dohme LLC$65Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy2019
2019-05-08Merck Sharp & Dohme LLC$40Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR2019
2019-05-08Merck Sharp & Dohme LLC$38Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR2019
2019-05-08Merck Sharp & Dohme LLC$35Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy2019
2019-05-08Merck Sharp & Dohme LLC$35Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy2019
2019-05-08Merck Sharp & Dohme LLC$35Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR2019
2019-05-08Merck Sharp & Dohme LLC$31Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy2019
2019-05-08Merck Sharp & Dohme LLC$30Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR2019
2019-05-08Merck Sharp & Dohme LLC$30Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy2019
2019-05-08Merck Sharp & Dohme LLC$23Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy2019
2019-05-08Merck Sharp & Dohme LLC$21Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy2019
2019-05-08Merck Sharp & Dohme LLC$20Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy2019
2019-05-08Merck Sharp & Dohme LLC$19Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy2019
2019-05-08Merck Sharp & Dohme LLC$19Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy2019
2019-05-08Merck Sharp & Dohme LLC$15Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy2019
2019-05-08Merck Sharp & Dohme LLC$12Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy2019
2019-05-08Merck Sharp & Dohme LLC$12Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy2019
2019-05-08Merck Sharp & Dohme LLC$12Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy2019
2019-05-08Merck Sharp & Dohme LLC$10Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy2019
2019-05-08Merck Sharp & Dohme LLC$6Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy2019
2019-05-08Merck Sharp & Dohme LLC$4Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR2019
2019-05-08Merck Sharp & Dohme LLC$4Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR2019
2019-05-08Merck Sharp & Dohme LLC$3Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR2019
2019-05-08Merck Sharp & Dohme LLC$3Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy2019
2019-05-08Merck Sharp & Dohme LLC$2Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR2019
2019-05-08Merck Sharp & Dohme LLC$2Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR2019
2019-05-08Merck Sharp & Dohme LLC$1Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR2019
2019-05-08Merck Sharp & Dohme LLC$1Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR2019
2019-05-08Merck Sharp & Dohme LLC$1Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy2019
2019-05-08Merck Sharp & Dohme LLC$0Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy2019
2019-05-08Merck Sharp & Dohme LLC$0Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy2019
2019-05-08Merck Sharp & Dohme LLC$0Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYPEMBROLIZUMAB IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA AMBASSADOR2019
2019-05-08Merck Sharp & Dohme LLC$0Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy2019
2019-05-08Merck Sharp & Dohme LLC$0Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy2019
2019-05-08Merck Sharp & Dohme LLC$0Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy2019
2019-05-08Merck Sharp & Dohme LLC$0Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy2019
2019-04-30Novo Nordisk AS$72Research paymentIn-kind items and servicesNN9931-42962019
2019-04-25Novo Nordisk AS$6,495Research paymentCash or cash equivalentNN9931-42962019
2019-04-25Novo Nordisk AS$4,410Research paymentCash or cash equivalentNN9931-42962019
2019-04-25Novo Nordisk AS$3,420Research paymentCash or cash equivalentNN9931-42962019
2019-04-17Insulet Corporation$352Compensation for services other than consulting, including serving as faculty or as a speaker at a v (10 payments)Cash or cash equivalentOmnipod Device, Insulin Pump2019
2019-04-15Merck Sharp & Dohme LLC$17Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy2019
2019-04-12Stryker Corporation$296Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREPROCESSED DEVICE Device, HYGIA HEALTH SERVICES2019
2019-04-12Stryker Corporation$117Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREPROCESSED DEVICE Device, HYGIA HEALTH SERVICES2019
2019-04-12Stryker Corporation$34Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREPROCESSED DEVICE Device, HYGIA HEALTH SERVICES2019
2019-04-12Stryker Corporation$27Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentREPROCESSED DEVICE Device, HYGIA HEALTH SERVICES2019
2019-04-11Novo Nordisk AS$4,000Research paymentCash or cash equivalentEX9536-43882019
2019-04-11Novo Nordisk AS$1,500Research paymentCash or cash equivalentEX9536-43882019
2019-04-10Insulet Corporation$1,760Compensation for services other than consulting, including serving as faculty or as a speaker at a v (10 payments)Cash or cash equivalentOmnipod Device, Insulin Pump2019
2019-04-08Merck Sharp & Dohme LLC$212Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy2019
2019-04-08Merck Sharp & Dohme LLC$205Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy2019
2019-04-08Merck Sharp & Dohme LLC$42Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy2019
2019-04-08Merck Sharp & Dohme LLC$17Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy2019
2019-04-08Merck Sharp & Dohme LLC$13Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Randomized, Double-Blind, Phase III Study of Pembrolizumab versus Placebo in Combination with Neoadjuvant Chemotherapy2019
2019-04-01Merck Sharp & Dohme LLC$232,104Consulting FeeCash or cash equivalent2019

The latest 200 records of 238.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Schuylkill CountyPottsville city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Pottsville, PA, county Schuylkill County, PA, state Pennsylvania; placed by its city name.

MeasurePlace (city or town)
Pottsville, PA
County
Schuylkill County, PA
State
Pennsylvania
Population B0100313,364143,55813,018,639
Population, 2020 census P113,346143,04913,002,700
Median age B0100243.443.740.9
Under 18 B0100119.8%19.9%20.4%
65 and over B0100121.5%21.1%19.5%
Households B110016,00157,9885,274,853
Foreign born B050021.0%2.7%7.7%
Median household income B19013$54,332$68,313$77,971
Median family income B19113$65,065$80,961$100,262
Per capita income B19301$30,888$34,954$44,355
Poverty rate B1700119.9%12.8%11.7%
Unemployment rate B230257.2%5.6%5.3%
Civilian labor force B230256,49668,4426,684,175
Mean commute (minutes) B0801324.327.326.3
Bachelor's degree or higher B1500321.9%19.9%35.2%
Housing units B250016,97267,2955,806,452
Owner-occupied B2500357.1%76.1%69.3%
Renters B2500342.9%23.9%30.7%
Median home value B25077$100,500$153,000$254,500
Median gross rent B25064$822$876$1,209
White, not Hispanic B0300285.6%86.2%73.0%
Black B030021.8%2.6%10.3%
Hispanic or Latino B030028.8%7.8%8.7%
Asian B030020.2%0.5%3.8%
American Indian and Alaska Native B030020.0%0.0%0.1%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Pottsville, PA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.